COVID-19 is accelerating digital transformation

 No one in pharma needs to be told that COVID-19 is upending business as we know it. But in the face of this unprecedented change there is a great opportunity to adapt, improve and profit from new ways of working. And digital capabilities are the key to realising them, says Bertrand Bodson, Chief Digital Officer and Member of the Executive Board of Novartis in his keynote speech opening the eyeforpharma Virtual, a digital version of the Barcelona event, and available to delegates who can sign up for free athttps://virtual.eyeforpharma.com. Novartis is demonstrating how pharma can achieve rapid transformation and increase customer engagement from disruption thanks to the extensive digital investments it has made across the business in the last two and a half years.   Remote capabilitiesThis investment has primed it to be able to react rapidly and flexibly in the last few weeks. “These are extraordinary times, extraordinary circumstances in which we have been tested in so many ways. We are seeing fundamental change happening at record time and digital has been at the centre of this,” says Bodson. At Novartis, clinical trials teams are able to work remotely and virtually, via its Sense insight centre and its Nerve Live platform, giving them the capability to continue working and the clarity to understand the progress of trials in real time.   “We are very fortunate that we made massive investments over the past couple of years in the underlying platform that allows...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news